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Abstract 
Inflammation of the brain is increasingly recognised as important in encephalitis. The 
high mortality and morbidity rates of acute neuroinflammatory diseases has directed 
significant interest in the investigation of biomarkers to define neuroinflammation 
and explore mechanisms involved in the regulation of central nervous system 
immune responses. Metabolomics is a rapidly emerging research field increasingly 
recognised as a powerful approach for addressing the gaps in knowledge underlying 
the pathophysiologic mechanisms involved in neuroinflammation and accurate 
diagnostic biomarkers.  
 
The advancements in analytical platforms followed by subsequent chemometrics 
tools have revolutionised untargeted metabolomics analyses. With liquid 
chromatography coupled to high resolution mass spectrometry moving to the 
forefront, an untargeted metabolomics analysis method was developed and 
optimised to identify multi-class metabolites in human cerebrospinal fluids.  The 
detection of cerebrospinal fluid metabolites were determined based on a simple and 
rapid methanol precipitation sample preparation method. The chromatographic 
separation was achieved within a twenty minute gradient elution using hydrophilic 
interaction chromatography. The method exhibited good reproducibility, high 
efficiency chromatographic separation and strong mass resolving mass spectrometry 
analysis. The practicality and robustness of the developed method on a pilot study 
further demonstrated the potential of the untargeted metabolomics strategy to 
identify biomarkers and understand the biochemical pathways involved in 
neuroinflammation.  
 
With metabolites as the downstream products of cellular function, the application of 
metabolomics data is to understand the pathogenesis of neuroinflammatory 
mechanisms involved in encephalitis. Preliminary evidence showed statistically 
Abstract 
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discriminative metabolites in the tryptophan-kynurenine pathway, nitric oxide 
pathway and elevation of neopterin. The use of the adjacent ratios such as 
kynurenine/tryptophan, anthranilic acid/3-hydroxyanthranilic acid and 
ADMA/arginine in combination with neopterin can serve as a potential cerebrospinal 
fluid biomarker panel to predict neuroinflammation, particularly when routine tests 
and neuroimaging return a negative result in encephalitis patients.  The emergence of 
cerebrospinal metabolomics holds significant promise incorporating omics research 
into a clinical diagnostic service. 
 
 
